XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Revenues:        
Revenue from collaborative research $ 20,111,173 $ 15,532,680 $ 42,015,994 $ 50,283,510
Grant revenue 120,895 548,864 1,112,238 3,744,047
Total revenues 20,232,068 16,081,544 43,128,232 54,027,557
Costs and expenses:        
Research and development 11,087,919 11,968,253 32,233,828 36,924,987
General and administrative 1,986,555 1,514,334 7,322,974 6,640,740
Total costs and expenses 13,074,474 13,482,587 39,556,802 43,565,727
Income (loss) from operations 7,157,594 2,598,957 3,571,430 10,461,830
Other income (expense) (553,612) 1,557 (627,281) 4,752
Net comprehensive income (loss) $ 6,603,982 $ 2,600,514 $ 2,944,149 $ 10,466,582
Basic net income (loss) per common share $ 0.14 $ 0.00 $ 0.00 $ 0.00
Diluted net income (loss) per common share $ 0.01 $ 0.00 $ 0.00 $ 0.00
Basic weighted average number of common shares 1,184,507 1,092,307 1,463,798 1,078,145
Diluted weighted average number of common shares 21,242,978 21,502,424 21,908,859 21,412,848